⁹⁹ᵐTc-Maraciclatide Phase I Data Published in Nuclear Medicine Communications

London, UK, 14 March 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ⁹⁹ᵐTc-maraciclatide, announces the publication of Phase I data demonstrating the safety, biodistribution and radiation dosimetry of ⁹⁹ᵐTc-araciclatide in the April 2024 edition of Nuclear Medicine Communications.

Share this article with a friend

Create an account to access this functionality.
Discover the advantages